, Decision_act (EU) 1980/1283

In forcesince 25 Nov 1980
30.

Moreover, in this case the export prohibition imposed by Ortho UK had restrictive effects.

Ortho UK's intention, to restrict competition within the common market, appears clearly from its efforts to discover, at the request and with the assistance of Cilag Alsbach, the dealers supplying Gravindex pregnancy tests to the German importer Eurim Pharm.

31.

In fact, Ortho UK did prevent dealers in the United Kingdom from reselling Gravindex pregnancy tests to Eurim Pharm. After threatening to withhold supplies from the chemist in April 1976, when Gravindex pregnancy tests originating from him continued to appear on the German market, in May 1977, Ortho stopped supplies of the products to certain chemists who, in Ortho UK's view, were apparently supplying German undertakings. At the same time orders from at least three chemists were considerably delayed.

32.

These facts show that the amendment of the export prohibition by Ortho UK was a pure fiction. In practice, Ortho UK acted as if there had not been any amendment ; so that the agreements operated as if they had never been amended.

33.

The parties claim that their actions are of too little importance to restrict competition within the common market to an appreciable degree.

However, it has been established (see figures under point 2 above) that the 1977 turnover of the Johnson & Johnson group in Europe was $ 600 million and the "operating profit" in Europe in that year was $ 137 million. In those figures the pharmaceutical sector comprises about 17 % and 30 % respectively.